Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6234 and AZD9550 in Chinese Participants Living With Obesity/Overweight
NCT07017179Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of lenbelintide and AZD9550 in obesity (6 arms), sponsored by AstraZeneca. Primary endpoint: Adverse Events and Serious Adverse Events at Day 225. Started May 2025; status: active, not recruiting.
02
Drugs
lenbelintideAZD9550
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07017179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07017179.